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1. Introduction 
Medullary thyroid carcinoma (MTC) is accounting for 5 - 8% of all thyroid cancers and 
arises from calcitonin producing parafollicular C cells of the thyroid gland. Mainly MTC is 
sporadic in nature, but in 20 - 30% of cases it is present in an autosomal dominant inherited 
pattern with defined phenotype referred as multiple endocrine neoplasia type 2 (MEN 2) 
and familial medullary thyroid carcinoma (FMTC). The identification of missense germline 
mutations in the RET proto-oncogene between 1993 and 1998 as the cause of MEN 2 and 
FMTC ushered in the molecular age. Specific mutations in the RET gene encoding a 
transmembrane tyrosine kinase result in "gain-of-function" of the receptor with definite 
changes in downstream signal transduction pathways. Intriguingly, examination of the 
mutated codons led to the growing recognition of a striking genotype–phenotype 
correlation between the transforming activity inherent in these mutations and disease onset 
and aggressiveness, implicating that manifestation and clinical progression is conditioned 
by the type of mutation. Detection of the mutant alleles in kindred members predicts disease 
inheritance and provides the basis for prophylactic thyroidectomy in children. This seminal 
discovery, enabling predictive testing, paved the way for an evidence-based practice of 
clinical cancer genetics. In case of novel RET mutations it is exceedingly important to clarify 
whether it represents a harmless polymorphism or a causative pathogenic mutation. For this 
purpose, we established a molecular diagnosis program that, in conjunction with clinical 
data, allows individualized risk stratification for patients.  
2. RET proto-oncogene and MTC 
2.1 RET proto-oncogene – Genotype to phenotype 
Transfection studies using DNA from human T cell lymphoma led to the isolation of a 
transforming gene called RET (REarranged during Transfection) that consists of two linked 
sequences caused by cointegration during transfection (Takahashi et al., 1985). The resulting 
chimeric gene encodes a fusion protein comprising an N-terminal region with a 
dimerization motif fused to a tyrosine kinase (TK) domain. Subsequently, the name RET has 
been retained to designate the gene coding for the tyrosine kinase domain of this fused 
oncogene. The human RET gene is localized on chromosome 10q11.2 (Donghi et al., 1989) 
and spans 21 exons. Homologues of RET have been identified in higher and lower 
vertebrates as well as in Drosophila melanogaster (Hahn and Bishop, 2001). The RET proto- 
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oncogene encodes a transmembrane receptor of the tyrosine kinase family with three major 
isoforms that arise through alternative splicing of the 3´-terminus, leading to expression of 
proteins that differ by their last 51 (RET51), 43 (RET43) or nine (RET9) amino acids, 
respectively (Manie et al., 2001). It is expressed primarily in neural crest and urogenital 
precursor cells, and is implicated in developmental processes, such as maturation of 
peripheral nervous system lineages, kidney morphogenesis or spermatogonia differentiation 
(Durbec et al., 1996; Meng et al., 2000; Schuchardt et al., 1994). Among them, RET9 and 
RET51 are the major isoforms consisting of 1072 and 1114 amino acids, respectively. The 
signaling complex associated with RET9 markedly differs from RET51-associated factors, 
which might have an influence on the higher transforming potential of the RET51 isoform 
(Le Hir et al., 2000; Tsui-Pierchala et al., 2002). The RET protein is composed of three 
functional domains: The intracellular tyrosine kinase domain, a transmembrane region and 
a stretch of four extracellular cadherin-like domains that are implicated in ligand binding. 
The extracellular domain consists of four cadherin-like regions and a cysteine-rich tract, 
which facilitates receptor dimerization upon ligand stimulation (Iwamoto et al., 1993; 
Takahashi et al., 1998). This region also contains several glycosylation sites (Takahashi et al., 
1991). The fully glycosylated form (170-175 kDa) of RET is found in the plasma membrane, 
while the 150-155 kDa species is believed to be an immature, partially processed form found 
only in the endoplasmic reticulum (ER). RET serves as a functional receptor for 
neurotrophic factors of the glial cell-line derived neurotrophic factor (GDNF) family: GDNF, 
neurturin, artemin and persephin (Ichihara et al., 2004; Takahashi, 2001). Binding to and 
activation of RET occurs via glycosylphosphatidylinositol-anchored as well as soluble co-
receptors that are designated as GDNF-family receptors (GFRs) α1-4 (Airaksinen and 
Saarma, 2002; Manie et al., 2001) (Fig. 1 A). Ligand stimulation leads to activation of the RET 
receptor by dimerization and subsequent autophosphorylation of intracellular tyrosine 
residues. These, in turn, serve as docking sites for a number of interacting molecules 
activating downstream signal transduction pathways (Chiariello et al., 1998; Hayashi et al., 
2001; Murakami et al., 1999). Although tyrosine residues 905, 981, 1015, 1062 and 1096 are all 
phopshorylated upon ligand binding, it is the phosphorylation of tyr1062 that plays a 
crucial role in RET signaling as it acts as a multifunctional docking site for many adaptor or 
effector proteins (Jijiwa et al., 2004).  
Autosomal dominant gain of function mutations in the RET proto-oncogene have been 
identified as the key cause for the development of the multiple endocrine neoplasia type 2 
(MEN 2) syndrome, which can be further divided into three distinct clinical 
manifestations MEN 2A, MEN 2B, and familial medullary thyroid carcinoma (FMTC) 
(Bocciardi et al., 1997; Carlomagno et al., 1997; Hofstra et al., 1994; Mulligan et al., 1993; 
Santoro et al., 1995). In addition, 30-70% of sporadic medullary thyroid carcinomas harbor 
a mutation in the RET gene. Mutations render the RET receptor constitutively active and 
display striking genotype-phenotype correlations. Patients with MEN 2A always develop 
medullary thyroid carcinoma (MTC), but also pheochromocytoma (50%) and parathyroid 
hyperplasia or adenoma (20-30%). MEN 2B, in contrast, is the most aggressive subtype 
and is characterized by the same features as MEN 2A, but with earlier onset and 
developmental abnormalities such as mucosal neuromas, intestinal ganglioneuromas, 
ocular and skeletal abnormalities (marfanoid habitus). The most indolent subtype FMTC 
is characterized by the incidence of MTC-only (Brandi et al., 2001). Mutations identified in 
more than 98% of MEN 2A patients affect one of six cysteine residues in the cysteine-rich 
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region at codons 609, 611, 618, 620 (exon 10), 630 or 634 (exon 11) and cause ligand-
independent homodimerization through covalent intermolecular disulphide bonds, 
resulting in subsequent constitutive activation of the RET kinase which, in turn, leads to 
permanent downstream signaling (Santoro et al., 1995) (Fig. 1 C). Approximately 87% of 
MEN 2A mutations affect codon 634 (Eng et al., 1996; Hansford and Mulligan, 2000). In 
contrast, mutations found in MEN 2B patients affect residues in the tyrosine kinase 
domain and activate the RET receptor in its monomeric state, thereby changing the 
substrate specificity towards other cellular substrates and downstream signaling 
pathways (Borrello et al., 1995; Murakami et al., 1999; Santoro et al., 1999) (Fig. 1 B).  
 
 
Fig. 1. Schematic mechanisms of RET tyrosine kinase activation in healthy status versus 
MEN 2B and MEN 2A. A) Normal RET activation by glial cell line-derived neurotrophic 
factor (GDNF). GDNF binds to GFRα and leads to RET dimerization and 
autophosphorylation. B) Constitutive RET activation by MEN 2B mutations. C) Ligand 
independent RET activation by MEN 2A mutations. CAD Cadherin like domain; Cys 
Cysteine-rich domain; TMD Transmembrane domain; TK Tyrosine kinase domain  
Moreover, increased autophosphorylation of tyrosine 1062 has been described (Bocciardi et 
al., 1997; Salvatore et al., 2001; Santoro et al., 1995). MEN 2B is primarily associated with a 
single missense mutation of codon 918 (M918T), which is detectable in more than 90% of 
MEN 2B patients (Carlson et al., 1994; Eng et al., 1996; Hofstra et al., 1994; Mulligan et al., 
1993). A smaller number of MEN 2B cases contain mutations at codon 883 (A883F) (Gimm et 
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al., 1997; Smith et al., 1997). Mutations identified in FMTC patients (for example at codons 
790, 791 or 844) are found in the cysteine-rich region as well as in the tyrosine kinase 
domain, and lead to low level activation of the RET kinase corresponding to the indolent 
penetrance phenotype of FMTC (Arighi et al., 2005; Manie et al., 2001). An overview about 
mutated codons at specific sites of the RET oncogene and the correlating clinical phenotype 
is mapped in Fig. 2. 
 
 
Fig. 2. Domain structure of the RET proto-oncogene: CAD Cadherin like domain; Cys 
Cysteine-rich domain; TMD Transmembrane domain; TK Tyrosine kinase domain. Arrows 
point to the affected protein domains and specify the mutated codons and the correlating 
clinical phenotype. 
2.2 Medullary thyroid carcinoma – Standard diagnosis and treatment 
In most cases, the prognosis for MTC patients is good after early diagnosis and intervention. 
Since 1994, genetic screening using DNA from peripheral blood has been available for MEN 
2. This method allows diagnosis prior to the onset of symptoms. Moreover, the MEN 2-
associated mutations, involving RET exons 8, 10, 11, 13, 14, 15 and 16 are tested routinely. 
Currently, early genetic screening for RET mutations is considered the standard of care for 
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MEN 2 (Eng, 1999). Preoperative measurement of serum calcitonin is another highly 
sensitive method to establish the diagnosis of MTC. However, since germline RET 
mutations have been identified as a cause of MEN 2, the use of additional measurement of 
calcitonin is questionable. Though calcitonin levels can be helpful in determining the extent 
of disease and the extent of surgery required (Gimm, 2001).  
At present treatment of MTC is restricted to surgical removal of neoplastic tissue, and cure 
is only achieved when the disease is restricted to the thyroid gland. The general 
recommendation to perform total thyroidectomy seems to be justified since MTC is often 
multifocal and not susceptible to radioiodine ablation. Overall, RET mutations are classified 
into three groups based on the level of risk (or aggressiveness) for MTC (Sippel et al., 2008). 
Level 3 mutations (codon 883, 918, and 922) have the most aggressive course, with 
metastatic disease presenting in the first years of life. Because of the high risk for 
malignancy at an early age, thyroidectomy is recommended within the first 6 months of life 
and preferably within the first month of life (Brandi et al., 2001). Level 2 RET mutations 
(codon 611, 618, 620, and 634 mutations) are considered high risk for MTC and the current 
recommendation is that these patients undergo thyroidectomy before the age of 5 years. 
Mutations at codon 609, 768, 790, 791, 804 and 891 are classified as level 1. Patients carrying 
these mutations are still considered high risk for MTC but with the lowest risk of the RET 
mutations. MTC in these patients tends to develop later in life and takes on a more indolent 
course. Because clinically apparent disease is rarely reported prior to 10 years of age, many 
recommend waiting until then to perform a thyroidectomy. Based on more detailed research 
and knowledge the stratification system for RET germline mutations was recently 
reclassified by the Amercian Thyroid Association (ATA) into categories of increasing risk: 
class A (codons 768, 790, 791, 804, 891), class B (codons 609, 611, 618, 620, 630), C (codon 
634), and D (codon 883, 918), with level A representing lowest risk (FMTC) and level D 
representing the highest risk (MEN 2B) class (Kloos et al., 2009).  
Patients with unresectable or metastatic disease display a poor prognosis because radiation 
and chemotherapy have only a limited role (Cohen and Moley, 2003). Although MTC is less 
radiosensitive, radiotherapy is used as a palliative for symptomatic bone, central nervous 
system and mediastinal metastases. Some studies suggested a specific radiotherapy for MTC 
based on the selective uptake of [131I]MIBG and [111In]pentetreotide (Forssell-Aronsson et al., 
1995; Troncone et al., 1991) also concerning their role in diagnosis of neuroendocrine tumors 
and to some degree localisation of metastases (Kaltsas et al., 2001). Other nuclear 
approaches using radionuclide-labeled antibodies combined with pretargeting strategies to 
improve uptake of these antibodies have raised interest in targeted radiotherapy for MTC 
(Juweid et al., 1996; Juweid et al., 2000; Kraeber-Bodere et al., 1999; Mirallie et al., 2005).  
Since activated RET is proven to be causative for the development of MTC, molecular 
strategies to inhibit its activity or expression in cancer cells are highly promising. Targeting 
the enzymatic activity of tyrosine kinases by small molecule inhibitors like STI571 (Gleevec® 
or Imatinib), BAY 43-9006 (Sorafenib), allyl-geldanamycin, or arylidine 2-indolinone (RPI-1) 
selectively inhibit RET kinase activity and cell growth (Cohen et al., 2002; Lanzi et al., 2000). 
For example, oral daily RPI-1 treatment reduces the growth of human medullary thyroid 
carcinoma xenografts in mice by 81% (Cuccuru et al., 2004). Also, two indolocarbazole 
derivatives, CEP-701 and CEP-751, have been shown to effectively block RET 
phosphorylation at nanomolar levels and MTC cell growth (Strock et al., 2003), whereas the 
pyrazolo-pyrimidine PP1 inhibits tumorigenesis induced by RET/PTC oncogenes and 
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causes degradation of activated membrane-bound RET receptors through proteosomal 
targeting (Carlomagno et al., 2002b; Carniti et al., 2003; Strock et al., 2003). In addition, the 
pyrazolo-pyrimidine PP2, and the 4-anilinoquinazoline ZD6474 (Vandetanib) displayed a 
strong inhibitory activity towards constitutively active oncogenic RET kinases (Carlomagno 
et al., 2003; Carlomagno et al., 2002a). However most of the tyrosine kinase inhibitors are 
mulitkinase inhibitors and are also active against multiple signaling molecules (Santarpia et 
al., 2009). Moreover, some RET mutations (e.g. valine 804) cause resistance to these drugs 
(Carlomagno et al., 2004). Finally the efficacy in human patients has to be proven by 
treatment. Until now first clinical trials with several kinase inhibitors showed no beneficial 
or only moderate effects of the drugs (Table 1). Thus, development and evaluation of novel 
treatment strategies, including gene therapeutic approaches are further needed. 
 
Kinase inhibitor Clinical trial Reference 
Imatinib Phase II de Groot et al., 2007 
Sorafenib Phase II Lam et al., 2010 
Vandetanib Phase III Wells et al., 2010 
Sunitinib Phase II De Souza et al., 2010 
Motesanib Phase II Schlumberger et al., 2009 
Table 1. Summary of some tyrosine kinase inhibitors used in clinical trials 
Gene therapy is attractive for thyroid cancer treatment because of the possibility to selectively 
target therapeutic genes by application of tissue-specific promoters, such as the thyroglobulin 
or the calcitonin promoter. A range of therapeutic strategies were under investigation utilizing 
various genes: pro-drug activating genes (herpes simplex virus thymidine kinase /ganciclovir 
and purine nucleoside phosphorylase/fludarabine), the nitric oxide synthase II gene in a direct 
toxin therapy, gene for IL-12 in an immune stimulation strategy, and the expression of the 
sodium iodide symporter gene in radiotherapy application (Spitzweg and Morris, 2004). 
Moreover, molecular mimics (competition) directed toward specific mutations of RET by using 
the mutant EC-RET C634Y that is able to inhibit the membrane bound receptor RETC634Y 
through interfering with its dimerization (Cerchia et al., 2003).  
Another attractive approach is to block oncogenic signal transduction either by reducing 
RET expression or by interfering with receptor autophosphorylation using dominant-
negative RET protein. In this regard, adenovirus (Ad)-mediated expression of RET 
containing mutations in the N–terminal region of the extracellular domain such as HSCR32 
associated with Hirschsprung´s disease or FLAG has been shown to substantially inhibit 
receptor maturation, thereby preventing its transport to the membrane (Drosten et al., 2002; 
Drosten et al., 2003). These molecules proved to be highly active against MTC in cultures of 
human TT cells, which harbour the RETC634W mutation, and after inoculation of ex vivo 
infected tumor cells into nude mice. A second dominant-negative RET protein (RET∆TK), 
lacking the intracellular tyrosine kinase domain, showed the ability to block oncogenic 
activated RET autophosphorylation by forming an inactive dimer with the mutated RET 
receptor. Transduction of TT cells with RET∆TK resulted in decreased cell-cycle progression, 
but also, more importantly induction of cell death by apoptosis. Activity of RET∆TK against 
MTC was also demonstrated in RET transgenic mice, which develop orthotopic tumors in 
the thyroid. Injection of an Ad vector expressing dominant-negative RET protein into MTC 
of the thyroid glands significantly decreased the tumor size after two weeks (Drosten et al., 
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2004). To enhance tumor specificity of anti-RET Ad vectors in order to target systemically 
spreaded medullary thyroid carcinoma cells, we have recently identified a number of MTC-
specific peptides that can be used to efficiently redirect the therapeutic gene to primary 
MTC, their migrating populations, and potentially tumor metastases under in vivo 
conditions (Böckmann et al., 2005a; Böckmann et al., 2005b; Schmidt et al., 2011). 
3. Combining tools – RET molecular diagnostics  
RET gene analysis widely used to identify carriers at risk of developing medullary thyroid 
cancer, occasionally uncovers novel sequence variants of unknown clinical significance. For 
these newly identified or rare mutations in the RET gene, the causative role of the mutation 
and the genotype-phenotype relationship must be evaluated to define the mutation´s codon-
specific risk level. For this purpose, we have implemented a molecular diagnostic approach 
that allows us to classify RET mutations into one of the four clinical risk groups. Based on 
such molecular diagnosis recommendations for treatments of patients with hitherto 
undefined RET mutations are made. The program established allows direct translation of a 
genetic event into individualized clinical settings and is critical for treating physicians to 
decide whether a prophylactic thyroidectomy is necessary or not. Considering the potential 
risks after thyroidectomy e.g. reduced flexibility of the vocal cord and subsequent 
restrictions for the patient like hormone replacement therapy, molecular diagnostics in 
MTC-treatment have a direct impact on affected patients.  
3.1 From clinical RET mutation analysis to functional in vitro and in vivo 
characterization 
Clinical classification and DNA based screening 
Diagnosis of putative carriers of RET genes with novel mutations starts with clinical work 
up and subsequent RET mutation analysis. Therefore preoperatively basal and pentagastrin-
stimulated calcitonin levels, as a marker for MTC tumors, are determined by appropriate 
chemiluminescence assay. By utilizing histology analysis after total thyroidectomy tumor 
staging is performed according to the International Union Against Cancer tumor-node-
metastasis (TNM) classification from 1997. To detect mutations genomic DNA is isolated 
and five fragments covering the exons 8, 10, 11 and 13 to 16 of the RET proto-oncogene are 
amplified with exon specific PCR primers using high-fidelity PCR systems. The resulting 
fragments are sequenced to specify the point mutation.  
Construction and characterization of mutant RET expressing cell lines in vitro 
On the basis of the clinical findings the first goal is to determine whether a particular mutation 
is capable of converting RET into a dominantly transforming oncogene. At this point wet lab 
work starts to generate a RET51 mutant with defined specific mutation. pLPCX vectors are 
used to express the mutated RET gene. The pLPCX vector contains elements derived from 
Moloney murine leukemia virus (MoMuLV) and Moloney murine sarcoma virus (MoMuSV), 
and is mostly designed for retroviral gene delivery and expression. The cDNA fragment 
encoding the human tyrosine kinase RET51wt is ligated downstream from the CMV promoter 
of pLPCX retroviral vector (Fig. 3 A). pLPCX expression vectors containing the selected RET 
point mutation are generated by site directed mutagenesis using primers harboring the 
desired codon and pLPCX RET51wt plasmid as a template. All constructed plasmids are 
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routinely sequenced to confirm the presence of the desired mutations. NIH3T3 fibroblasts 
were chosen as in vitro model because they do not express endogenous RET protein and are 
generally accepted as a reliable transformation system to study oncogene function. In order to 
investigate the effects of mutated RET proteins on cellular transformation, NIH3T3 mouse 
fibroblasts are stably transfected with the pLPCX-RET expression vector. Single puromycine-
resistant clones are separated by limited dilution, cultivated and finally checked for RET 
protein expression (Fig. 3 B). After construction of the desired cell line a plethora of assays is 
applied to determine specific cellular parameters that help to evaluate aggressiveness of the 
investigated receptor mutant (Fig. 3 C). 
 
 
Fig. 3. Schematic workflow for generation and characterization of mutant RET-expressing 
NIH3T3 stable cell lines and in vitro assays. A) Site directed mutagenesis of RET51 wildtype 
containing retroviral plasmid to gain oncogenic RET point mutations. B) Transfection of 
NIH3T3 with mutant RET gene followed by clonal selection and subsequent control of RET 
protein levels of stably expressing NIH3T3-RET cell lines. C) Established in vitro assays 
from selected RET clones for evaluation of the transforming potential of single RET mutants. 
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1. Tyrosine kinase activity induced by mutated RET proteins: Protein extracts from 
NIH3T3 transfectants stably expressing mutated forms of RET are immunoprecipitated 
with an anti-RET antibody and subjected to a kinase assay. 
2. Analysis of growth properties by determining the proliferation rate through cell 
counting or cell viability assays. 
3. Apoptosis resistance: DNA-Damage induced cell death is activated by 
chemotherapeutics like doxorubicine or cisplatin. Subsequent killing of cells expressing 
oncogenic RET mutants is measured by flow cytometry. Here, propidium iodide 
staining is used to analyze cellular DNA content and look for sub-diploid or apoptotic 
cell population, respectively. 
4. Anchorage-independent growth as one of the most important oncogenic properties of 
cancer cells is determined by soft agar assays. Therefore, stable NIH3T3 transfectants 
are seeded in semisolid medium and cultured over a period of 30 days. Formed cell 
colonies are stained and counted under the microscope. 
5. Migration and invasiveness are major characteristics describing the aggressiveness and 
metastatic behavior of cancer cells. NIH3T3 fibroblasts expressing distinct mutant RET 
proteins are tested for their motility by matrigel invasion assays in Boyden chambers. 
Boyden chamber inserts contain membranes that are permeabilized by small pores 
coated with Matrigel™-Basement-Matrix. Hereon cells are seeded in serum-free 
medium. Medium containing a high concentration of fetal calf serum is added as 
chemoattractant in the lower chamber. Staining of cells enables examination of 
migrated cells under a fluorescence microscope. 
In all experiments established, already characterized NIH3T3 transfectants harboring well 
known point mutations in the RET gene like Y791F (FMTC), C634R (MEN 2A) and M918T 
(MEN 2B) with a defined genotype to phenotype correlation (Mise et al., 2006) are carried along 
as standard to classify new point mutations of as yet unknown oncogenic potential. In addition, 
short-term cultured parental NIH3T3 cells are employed as untransformed negative control. 
Establishing tumor allografts in nude mice through injection of NIH3T3-RET cell lines 
To investigate the transforming potential and aggressiveness of a particular RET mutant in 
vivo, experimental research in animal models is needed (Fig. 4). As in vivo transformation 
model, athymic nude mice are used. NIH3T3 stable transfectants are subcutaneously injected 
into the hind flank of 6 to 8 weeks old mice. Parental NIH3T3 cells are used as negative 
control. After injection tumor formation is monitored over time. To estimate the growth rate, 
tumor dimensions are measured with calipers every 2 days. Tumor volumes are calculated by 
the rotational ellipsoid formula: V=AxB2/2 (A-axial diameter; B-rotational diameter). Finally, 
after sacrificing the animals, tumors are removed, weighted, embedded in paraffin and 
submitted to immunohistochemistry. In detail, tumor sections carrying RET mutations are cut, 
dewaxed, rehydrated and probed with antibody against Ki-67 nuclear antigen, which 
recognizes actively proliferating cells. The percentage of proliferating cells can be determined 
by counting Ki-67 positive cells under a bright-field microscope. At the same time tumors can 
also be subjected to gene expression analysis. Therefore, tumor tissues are snap frozen in 
liquid nitrogen and stored at -80°C. RNA and protein extracts from samples are isolated by 
grinding 1 g of frozen tissue into a fine powder using a cold mortar and pestle by standard 
procedures for subsequent western blot and/or qPCR analysis. 
www.intechopen.com
  
Contemporary Aspects of Endocrinology 
 
260 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Induction of RET tumor formation by subcutaneous injection of stable NIH3T3 
transfectants. Measurement of tumor volume and immunohistochemical examination of 
cancer cell proliferation allows estimation of tumor aggressiveness. 
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3.2 Fingerprinting of RET-derived tumors by microarray analysis 
Our main concern is to find genotype-associated molecular signatures that could predict the 
onset and aggressiveness of MEN 2-RET-related MTCs with a defined point mutation. 
Therefore, we generated transcriptomic profiles of RET-derived tumors differing in their 
clinical appearance (FMTC, level 1; MEN 2A, level 2; MEN 2B, level 3). This genetic 
fingerprint library is compared with the expression profile of a tumor with an unclassified 
RET-mutation. Consequently a hitherto clinically undefined mutation is classified into the 
three risk levels. 
Identification of the differential gene expression pattern for a specific RET point mutation 
First, a GeneChip expression analysis is performed for the investigated RET-derived tumor  
(Fig. 5). Total RNA from frozen tumor tissue is used to prepare biotinylated cRNA targets, 
which are hybridized to Affymetrix Mouse 430 2.0 GeneChips. Hybridization and washing 
of gene chips is routinely performed on an Affymetrix GeneChip Hybridization Oven and 
Fluidics Station. Afterwards microarrays are analyzed by laser scanning (Affymetrix Gene-
Chip Scanner). Background-corrected signal intensities are determined and processed using 
MAS5 function of the R/Bioconductor affy package (www.r-project.org/ 
www.bioconductor.org). All calculations including normalization of microarray data, 
statistical tests, clustering, and further filtering methods are accomplished by up to date 
gene expression analysis software (e.g. GeneSpring GX 9.0 Agilent Technologies). Genes 
whose transcripts are not detected in any of the investigated mutations are excluded from 
statistical analysis to reduce the number of false positive genes. To determine differentially 
expressed genes, expression data are statistically analyzed using t-test and multiple testing 
correction (Benjamini and Hochberg False Discovery Rate). Cut-offs are set empirically to 
three fold and P ≤ 0.01.  
Analyzing and classifying the array data 
The methods described above generate a gene list and expression profile that is unique for a 
certain point mutation. The obtained expression profile is normalized and clustered together 
with our pre-existing RET tumor transcriptomic database. This allows us to estimate the 
potential outcome of a RET point mutation on the genetic level. Information about biological 
processes and signaling pathways that participate in RET-induced cellular transformation 
are from outstanding importance, because this could reveal attractive therapeutic targets 
such as small molecules inhibitors. To extract therapy relevant information, functional 
annotation clustering is applied by using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/). This online database 
provides a comprehensive set of functional annotation tools to understand biological 
meaning behind large list of genes. In detail, functional annotation clustering condenses an 
input gene list into smaller, much more organized biological annotation modules in a term-
centric manner. It allows investigators to focus on the annotation group level by quickly 
organizing many redundant/similar/hierarchical terms within the group. Annotation 
clusters, such as immune response, transcriptional regulation, chemokine activity, cytokine 
activity, kinase activity, signaling transduction, cell death and so on, could be found on the 
top of the output as expected for this study. With these results one can quickly focus on the 
major biology at an annotation cluster level. The enrichment score is to rank the overall 
importance (enrichment) of annotation term groups. It is the geometric mean of all the 
enrichment P-values of each annotation term in the group. 
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Fig. 5. Microarray data mining and expression analysis strategies to classify RET tumors 
with uncharacterized point mutations. Functional annotation clustering can be used to 
identify targets with therapeutic potential. 
Expression profiling identified a statistically significant modification of 1494 genes, 628 down- 
and 866 upregulated in MEN 2B compared with MEN 2A/FMTC tumors. By contrast, no 
obvious alterations were observed among individual MEN 2B and MEN 2A type mutations, or 
between MEN 2A and FMTC. Functional clustering of differential genes revealed RET-MEN 
2B specific upregulation of genes associated with novel growth and survival pathways. A 
central finding of this study was the extent of changes in genes whose products affect the 
immune response. In particular, we observed a remarkable accumulation of genes encoding 
NK cell receptors, T-lymphocyte antigens, regulators of NK- and T-cell 
proliferation/attraction, and apoptosis molecules important for the ability of NK cells and 
cytotoxic T cells to kill their targets in the tumors initiated by RET-MEN 2A/FMTC mutations, 
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while expression of these genes was nearly completely suppressed in RET-MEN 2B related 
cancers. Quantitative real-time PCR on tumors versus cultured NIH-RET cell lines 
demonstrated that they are largely attributed to the host innate immune system, whereas 
expression of CX3CL1 involved in leukocyte recruitment is exclusively RET-MEN 2A/FMTC 
tumor cell dependent. In correlation, massive inflammatory infiltrates were apparent only in 
tumors carrying MEN 2A/FMTC mutations, suggesting that RET-MEN 2B receptors 
specifically counteract immune infiltration by preventing chemokine expression, which may 
contribute to the different clinical outcome of both subtypes (Engelmann et al., 2009). In 
summary, our data support a model of RET oncogene-specific interference with the host 
immune system, in which chemokine production by RET-MEN 2A/FMTC cancer cells 
initiates an antitumor immune attack, while RET-MEN 2B receptors avoid tumor infiltration as 
a mechanism of evasion that may be critical for the different clinical outcome of both subtypes. 
4. Conclusion and future perspectives 
In 1993, activating mutations in RET were identified as a cause for the development of MTC. 
In the following years, extensive research has been dedicated to exploring the mechanisms 
involved in RET-mediated tumorigenesis. All acquired data emphasize the essential role of 
mutated RET in the process of MTC development and already indicate a role for RET as an 
anticancer target. In recent years, many different studies have experimentally verified that 
RET inhibition might have an adverse effect on MTC progression, and that oncogenic 
activated RET is indeed a highly promising target for the development of a targeted 
strategy. Our results obtained from functional investigations of RET oncogene mutations 
imposingly demonstrate how clinical practice is empowered by molecular information that 
dictates medical management, lending future credence to the concept of gene-informed 
personalized healthcare. In the molecular age, however, it would be farfetched to believe 
that focussing on the DNA levels is the entire truth to solve an individual´s prognosis. 
Downstream of the transcriptional level regulation of mRNA awaits to be the next step in 
oncogenesis research. At this point small non-coding microRNAs (miRNAs) appear on 
stage. The discovery of miRNAs and their impact on functions in many biological and 
physiological processes has opened a new broad area of possible interactions in the 
regulatory network of cells. Furthermore, in the past few years it became evident that these 
regulatory RNAs also have an emerging role in development and progression of tumors. 
Extensive profiling of miRNAs in many cancer types revealed significant differences in their 
expression patterns, making them an interesting tool for cancer treatment. Until now the 
expression and functions of miRNAs in thyroid cancers has been described for follicular, 
anaplastic and papillary thyroid carcinomas. The studies demonstrated that in these cancer 
types distinct miRNAs are up and down regulated. In turn, these miRNAs regulate several 
transcription factors and effector molecules that are implicated in proliferation, cell 
adhesion, apoptosis and finally lead to oncogenesis and de-differentiation. Thus, miRNAs 
can act as oncogenes or tumor suppressors in thyroid cancers. To date complete miRNA 
profiles of MTCs harboring distinct RET mutations are missing. An opportunity that must 
be exploited for moving towards individualized medicine in cancer treatment beyond ATA 
risk stratification or, even more important, for prevention of metastasis. The technical 
procedure developed in our laboratory to identify MTC-associated miRNAs contributing to 
the oncogenic potential of the mutated RET receptor are illustrated in Fig. 6. 
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Fig. 6. Real-time PCR based screening for microRNA profiles in various human MTCs 
harboring RET point mutations. Clustering is used to reveal differential expression patterns 
of distinct microRNAs in tumors compared to healthy donor tissue. 
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